Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE Therapeutics : Barclays Adjusts Price Target for VYNE Therapeutics to $15 From $12, Maintains Overweight Rating

03/08/2021 | 01:53pm EDT


ę MT Newswires 2021
All news about VYNE THERAPEUTICS INC.
10/05VYNE THERAPEUTICS : Partner Cutia Therapeutics Enrolls First Patient in Late-Stage Acne Dr..
MT
10/05VYNE Therapeutics Announces its China Partner’s Enrollment of First Patient in Phase 3 ..
CI
09/20VYNE THERAPEUTICS : to Present at the Cantor Fitzgerald Investment Conference
AQ
09/08VYNE THERAPEUTICS : to Present at the H.C. Wainwright Annual Investment Conference
AQ
09/03VYNE THERAPEUTICS INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08/18INSIDER TRENDS : Selling By Insiders Lingers at VYNE Therapeutics
MT
08/17INSIDER TRENDS : Insider Sales Add to 90-Day Trend at VYNE Therapeutics
MT
08/16INSIDER TRENDS : Insider 90-Day Selling Trend Prolonged at VYNE Therapeutics
MT
08/13VYNE THERAPEUTICS : Northland Adjusts VYNE Therapeutics' Price Target to $6 From $12, Keep..
MT
08/12VYNE THERAPEUTICS : Explanatory Note (Form 8-K)
PU
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 18,2 M - -
Net income 2021 -70,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,91x
Yield 2021 -
Capitalization 62,8 M 62,8 M -
Capi. / Sales 2021 3,44x
Capi. / Sales 2022 8,75x
Nbr of Employees 106
Free-Float 87,2%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,22 $
Average target price 6,67 $
Spread / Average Target 446%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-80.70%63
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
ELI LILLY AND COMPANY40.89%215 657